Antiretroviral Toxicity clinical trials at University of California Health
1 research study open to eligible people
Surveillance Monitoring for ART Toxicities Study in HIV Uninfected Children Born to HIV Infected Women
open to all eligible people
SMARTT will estimate the incidence of conditions and diagnoses potentially related to in utero exposure to antiretroviral therapy and/or exposure in the first two months of life among children born of HIV-infected mothers.
Our lead scientists for Antiretroviral Toxicity research studies include Stephen Spector, MD.